Skip to main content
SpringerLink
Log in

Post ASCO update 2016—lung cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The aim of this short review is to summarize the most important data relating to the field of thoracic tumors presented at the 2016 ASCO annual meeting. For small cell lung cancer (SCLC) the treatment algorithms once again remain unchanged. The CONVERT study was not able to show superiority of a modern chemoradiotherapy regimen using once daily fractionation over the historical standard of hyperfractionated chemoradiotherapy. With rovalpituzumab tesirine a promising new agent is in development, leading to encouraging treatment results in patients with pretreated, extensive SCLC disease on phase IB level. Regarding nonsmall cell lung cancer (NSCLC) a phase II trial was able to confirm high efficacy of the combination dabrafenib/trametinib if a BRAF-V600E mutation is detectable. These data should lead to more widespread implementation of BRAF mutation testing in routine diagnostic work-up. In the J‑ALEX trial alectinib outperformed crizotinib in the first-line treatment of Asian patients with ALK-rearranged metastatic NSCLC. However, further data from ongoing studies will be necessary to better define the optimal sequencing of treatments for this genetically defined subgroup of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Turrisi ET, Kyungmann K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and eoposide. New Engl J Med. 1999;340(4):265–71.

    Article  CAS  Google Scholar 

  2. Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85(4):1066–73.

    Article  Google Scholar 

  3. Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol. 2016;34(suppl):abstr 8504.

    Article  Google Scholar 

  4. Saunders LR, Bankovich AJ, Anderson WD, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136. doi:10.1126/scitranslmed.aac9459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rudin CM, Pietanza MC, Bauer TM, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr LBA8505.

    Article  Google Scholar 

  6. Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr 100.

    Article  Google Scholar 

  7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  Google Scholar 

  8. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121(3):448–56.

    Article  CAS  Google Scholar 

  9. Planchard D, Kim T, Mazieres J, et al. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small-cell lung cancer : a single-arm, multicenter, open-label, phase II trial. Lancet Oncol. 2016;17(5):642–50.

    Article  CAS  Google Scholar 

  10. Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncology. 2015;10(10):1451–7.

    Article  CAS  Google Scholar 

  11. Long GV, Stoyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicenter, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.

    Article  CAS  Google Scholar 

  12. Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(suppl):abstr 107.

    Article  Google Scholar 

  13. Solomon BJ, Mok T, Dong-Wan K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167–77.

    Article  Google Scholar 

  14. Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+NSCLC): Primary resultsfrom the J‑ALEX study. J Clin Oncol. 2016;34(suppl):abstr 9008.

    Article  Google Scholar 

  15. Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) form the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cel lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl):abstr 9009.

    Article  Google Scholar 

  16. Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012: Safety and efficacy of first-line (FL) nivolumab (nivo;N) and ipilimumab (ipi;I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34(suppl):abstr 3001.

    Article  Google Scholar 

  17. Kindler HL, Scherpereel A, Calabro L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, placebo-controlled, double blind phase III DETERMINE study. J Clin Oncol. 2016;34(suppl):abstr 8502.

    Article  Google Scholar 

  18. Giaccone G, Thompson J, Crawford J, et al. A phase II study of pembrolizumab for patients with recurrent thymic carcinoma. J Clin Oncol. 2016;34(suppl):abstr 8517.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Pneumology, Thoracic Oncology, Fachkliniken Wangen, Am Vogelherd 14, 88239, Wangen, Germany

    Georg Pall MD

Authors
  1. Georg Pall MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Pall MD.

Ethics declarations

Conflict of interest

G. Pall has received speakers honoraria from BMS, MSD, Roche, Novartis, Astra Zeneca and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pall, G. Post ASCO update 2016—lung cancer. memo 9, 215–218 (2016). https://doi.org/10.1007/s12254-016-0302-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0302-4

Keywords

Search

Navigation